drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (drug)
drug_description
Anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 to enhance T-cell priming and can deplete tumor regulatory T cells via FcγR-mediated ADCC/ADCP.
nci_thesaurus_concept_id
C2654
nci_thesaurus_preferred_term
Ipilimumab
nci_thesaurus_definition
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.
drug_mesh_term
Ipilimumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Human IgG1 monoclonal antibody against CTLA-4 that blocks CTLA-4-mediated inhibition to enhance CD28 costimulation and T-cell priming/activation, promoting antitumor cytotoxic T-cell responses; the IgG1 Fc can engage Fc-gamma receptors to deplete intratumoral regulatory T cells via ADCC/ADCP.
drug_name
Ipilimumab
nct_id_drug_ref
NCT06784648